MGNX
MacroGenicsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The post-earnings update was directionally better than the prior baseline because management paired the May 13, 2026 Q1 release with a clearer business reset: cash runway now extends through 2028 if the Bora deal closes, and the company still expects multiple 2026 pipeline milestones. Checked secondary coverage characterized the quarter as a slight EPS miss but a revenue beat, which is less important here than the reduced financing pressure and preserved catalyst calendar.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -12.9.
What can break
MacroGenics is a low-coverage small-cap biotech, so thin analyst follow-through, sparse external validation and a weak direct-peer set can amplify volatility around limited news flow.
Momentum
84
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.20 · Bull $6.50 · Bear $2.40
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $6.75
Why
Momentum84 · Δ7d -12.9
Value41 · Δ7d +0.0
Sentiment43 · Δ7d -6.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
84
26% active weight
Current posture
7d trendSoftening
Δ7d
-12.9
Δ21d
-13.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
43
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.2
Δ21d
+5.0
Why this grade
Composite grade C. Momentum 83.9 / Value 41.1 / Sentiment 42.7
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$274.59M
Beta
1.50
Shares Out
63.56M
P/E (TTM) · Derived
-3.7
P/S (TTM)
0.85
P/FCF (TTM) · Derived
-3.81
Rev YoY
+57.5%
EPS YoY
-11.1%
Gross Margin
+69.9%
Op Margin
-60.6%
Net Debt
-$83.15M
Current Ratio
1.90
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology